Strides Pharma Science’s board has approved demerger of Identified Business of Arco Lab, Wholly owned Subsidiary of the Company. The Board of Directors of Strides Pharma Science and Arco Lab have accorded their in-principle approval for the same in their meeting held on March 19, 2025. It is proposed to transfer by way of demerger the Life Sciences and Digital Innovation Capabilities (Identified Business) of Arco Lab into a New Company (NewCo). Such NewCo shall focus on Life Sciences and Manufacturing solutions with deep domain knowledge and cutting-edge technology capabilities.
Arco Lab will incorporate the NewCo to facilitate the proposed demerger including undertaking requisite preparatory steps viz., drawing up of the scheme of arrangement, valuation of the identified business, amongst others. The proposed structure envisages the NewCo to be a wholly owned subsidiary (WOS) of Strides and there will not be any impact on Strides, financially or otherwise arising out of the proposed restructuring.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1728.20 |
Dr. Reddys Lab | 1151.00 |
Cipla | 1475.00 |
Lupin | 2002.45 |
Zydus Lifesciences | 884.55 |
View more.. |